Related Experiment Videos
Relationship between CD44 expression and differentiation of human prostate adenocarcinomas
S Takahashi1, N Kimoto, S Orita
1First Department of Pathology, Nagoya City University Medical School, Nagoya, Japan. sattak@med.nagoya-cu.ac.jp
Cancer Letters
|August 26, 1998
Summary
CD44 isoforms like CD44H, v6, and v9 are common in prostate cancer. While CD44H, v6, and v9 correlate with tumor differentiation, they do not predict patient prognosis in prostate adenocarcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- CD44 is recognized for its significant role in tumor metastasis.
- Understanding the prognostic value of CD44 isoforms in prostate cancer is crucial for patient management.
Purpose of the Study:
- To investigate the correlation between CD44 isoform expression in prostate cancer cells and patient prognosis.
- To evaluate CD44H, CD44v6, and CD44v9 as potential biomarkers for prostate cancer differentiation and clinical outcomes.
Main Methods:
- Analysis of 72 prostate cancer biopsy specimens.
- Immunohistochemistry was employed to detect the expression of CD44H, CD44v6, and CD44v9 isoforms.
Main Results:
- CD44H (68.1%), CD44v6 (36.1%), and CD44v9 (68.1%) were frequently expressed isoforms.
- A positive correlation was observed between CD44H expression and tumor differentiation.
- CD44v6 and CD44v9 expression also showed potential as markers for prostate adenocarcinoma differentiation.
Conclusions:
- CD44H, CD44v6, and CD44v9 expression correlates with prostate cancer differentiation.
- These CD44 isoforms do not appear to be reliable predictors of clinical staging or patient prognosis in prostate cancer.